A systematic review 1 including 5 studies with a total of 907 subjects was abstracted in DARE. Pooled analysis did not show statistically significant difference between triple-drug therapy (cyclosporine A, prednisolone, and azathioprine) and double-drug therapy (cyclosporine A and prednisolone) in any of the reported outcome measures. There was a non-significant trend for better graft survival under the triple therapy (OR 0.82, 95% CI 0.61 to 1.16). Adverse reactions reported were hypertension (more frequent in the triple therapy group), increased rates of and carcinomas.
Comment: The quality of evidence is downgraded by imprecise results (few outcome events) and study quality.
Primary/Secondary Keywords